VIM and cancer: This post‐translational modification promotes PRMT1‐vimentin interaction and subsequent asymmetric dimethylation (aDMA) of vimentin at arginine (R64), driving cytoskeletal remodeling and metastatic competence in cancer cells (Figure 7).